Reversal of warfarin-induced coagulopathy after traumatic injury may be done exclusively with prothrombin complex concentrates (PCCs).
Teva Pharmaceutical announced that the New Drug Application (NDA) for SD 809 (deutetrabenazine) has been accepted by the FDA for...
- Amicus Therapeutics, Inc. reported that top-line data from the randomized, double-blind, placebo-controlled Phase III clinical study (ESSENCE, SD-005) to...
Teva Pharmaceutical Industries Ltd. announced the FDA has accepted the New Drug Application (NDA) and granted Priority Review for SD-809...
Teva Pharmaceutical Industries Ltd., announced positive top-line results from the pivotal clinical study Aim to Reduce Movements in Tardive Dyskinesia...
Auspex Pharmaceuticals, Inc. announced positive topline efficacy and safety results from its Phase III - First-HD.-registration trial evaluating SD-809 for...
Teva Pharmaceutical Industries Ltd. announced that it has received a Complete Response Letter (CRL) from the FDA regarding the New...
Teva Pharmaceutical has announced new data from the Phase III placebo-controlled and randomized First Time Use of SD 809 (deutetrabenazine)...
Auspex Pharmaceuticals has announced results from a pre-specified interim subgroup analysis of the ongoing open-label ARC-HD Switch study in which...
Teva Pharmaceutical Industries Ltd.announced SD-809 (deutetrabenazine) showed statistically significant results in the second Phase III registration trial studying the potential...